{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:41:10Z","timestamp":1777934470143,"version":"3.51.4"},"reference-count":79,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T00:00:00Z","timestamp":1600646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To summarize the proposed mechanisms behind hypertension and QT interval prolongation associated with use of targeted systemic cancer therapies and provide recommendations for monitoring or managing these toxicities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The cardiotoxic effects of targeted systemic cancer therapies represents a new paradigm of cancer treatment associated cardiovascular adverse events. National guidelines regarding optimal monitoring and management strategies for hypertension and QT interval prolongation associated with use of these therapies are lacking. While the pathophysiological drivers of hypertension due to targeted systemic cancer therapies differ by class of targeted therapy, general management strategies do not. Routine blood pressure monitoring throughout the duration of therapy is recommended for all agents. Patients who experience hypertension often can be treated with the addition or modification of antihypertensive therapies. Uncontrolled hypertension despite optimal medical management may require dose modifications or discontinuation of the targeted systemic cancer therapy. Electrocardiogram monitoring is recommended for patients who receive targeted therapies that may prolong the QT interval. Minimizing or managing drug interactions with other QT prolonging medications is recommended in addition to ensuring adequate electrolyte supplementation. Dose modifications or discontinuation of the targeted systemic therapy may be necessary for patients who experience QT interval prolongation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Appropriate cardiovascular monitoring and timely management of treatment-emergent toxicities can optimize therapy for patients receiving targeted systemic cancer therapies associated with a risk of drug-induced hypertension or QT interval prolongation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220958462","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T03:22:22Z","timestamp":1600658542000},"page":"1987-1996","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypertension and QT interval prolongation associated with targeted systemic cancer therapies"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9517-5281","authenticated-orcid":false,"given":"Olivia G","family":"Fahey","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Kansas Cancer Center, Westwood, KS, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer K","family":"Piccolo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, William S. Middleton Memorial Veterans Hospital, Madison, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason J","family":"Bergsbaken","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UW Health, Madison, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"N Dow-Hillgartner","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UW Health, Madison, WI, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,9,21]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1513488"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.349"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1586\/14779072.2015.1027686"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw211"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds293"},{"key":"e_1_3_2_7_2","unstructured":"U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute. Common terminology criteria for adverse events (CTCAE) https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf (2017 accessed 4 February 2020)."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e3283403806"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1586\/14779072.2015.1032940"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40885-019-0116-x"},{"key":"e_1_3_2_11_2","unstructured":"Alunbrig TM [package insert]. Cambridge MA: ARIAD Pharmaceuticals Inc. 2018."},{"key":"e_1_3_2_12_2","unstructured":"Imbruvica(R) [package insert]. Horsham PA: Pharmacyclics LLC 2019."},{"key":"e_1_3_2_13_2","unstructured":"Zytiga(R) [package insert]. Horsham PA: Janssen Biotech Inc. 2019."},{"key":"e_1_3_2_14_2","unstructured":"Zejula(R) [package insert]. Waltham MA: Tesaro Inc. 2019."},{"key":"e_1_3_2_15_2","unstructured":"Aliqopa TM [package insert]. Whippany NJ: Bayer HealthCare Pharmaceuticals Inc. 2019."},{"key":"e_1_3_2_16_2","unstructured":"Inlyta(R) [package insert]. New York NY: Pfizer Laboratories Div Pfizer Inc. 2019."},{"key":"e_1_3_2_17_2","unstructured":"Avastin(R) [package insert]. South San Francisco CA: Genentech Inc. 2019."},{"key":"e_1_3_2_18_2","unstructured":"Cabometyx(R) [package insert]. Alameda CA: Exelixis Inc. 2019."},{"key":"e_1_3_2_19_2","unstructured":"Cometriq(R) [package insert]. Alameda CA: Exelixis Inc. 2019."},{"key":"e_1_3_2_20_2","unstructured":"Lenvima(R) [package insert]. Woodcliff Lake NJ: Eisai Inc. 2019."},{"key":"e_1_3_2_21_2","unstructured":"Votrient(R) [package insert]. East Hanover NJ: Novartis Pharmaceuticals Corporation 2019."},{"key":"e_1_3_2_22_2","unstructured":"Iclusig(R) [package insert]. Cambridge MA: ARIAD Pharmaceuticals Inc. 2018."},{"key":"e_1_3_2_23_2","unstructured":"Cyramza(R) [package insert]. Indianapolis IN: Eli Lilly and Company 2019."},{"key":"e_1_3_2_24_2","unstructured":"Stivarga(R) [package insert]. Whippany NJ: Bayer HealthCare Pharmaceuticals Inc. 2019."},{"key":"e_1_3_2_25_2","unstructured":"Nexavar(R) [package insert]. Whippany NJ: Bayer HealthCare Pharmaceuticals Inc. 2018."},{"key":"e_1_3_2_26_2","unstructured":"Sutent(R) [package insert]. New York NY: Pfizer Laboratories Div Pfizer Inc. 2019."},{"key":"e_1_3_2_27_2","unstructured":"Caprelsa(R) [package insert]. Wilmington DE: AstraZeneca Pharmaceuticals LP 2016."},{"key":"e_1_3_2_28_2","unstructured":"Zaltrap(R) [package insert]. Bridgewater NJ: Sanofi-Aventis 2020."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.12951"},{"key":"e_1_3_2_30_2","first-page":"269","article-title":"RAAS inhibition and mortality in hypertension","volume":"2013","author":"Ferrari R.","year":"2013","unstructured":"Ferrari R. RAAS inhibition and mortality in hypertension. Glob Cardiol Sci Pract 2013; 2013: 269\u2013278.","journal-title":"Glob Cardiol Sci Pract"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019833992"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S142264"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-016-3198-0"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0042"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.01.011"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.184812"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.157727"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211228"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25546"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-010-0150-2"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1513489"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.284427"},{"key":"e_1_3_2_43_2","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"71","author":"Whelton PK","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, et\u00a0al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines. Hypertension 2018; 71: e13\u2013e115.","journal-title":"Hypertension"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq091"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr128"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.11.2011.5238"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.11.021"},{"key":"e_1_3_2_48_2","unstructured":"Cardizem(R) [package insert]. Bridgewater NJ: Bausch Health US LLC 2020."},{"key":"e_1_3_2_49_2","unstructured":"Verelan(R) [package insert]. Philadelphia PA: Lannett Company Inc. 2020."},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1042\/bse0500161"},{"key":"e_1_3_2_51_2","unstructured":"Coreg [package insert]. Research Triangle Park NC: GlaxoSmithKline 2017."},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.04.009"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v7.i6.315"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00922"},{"key":"e_1_3_2_55_2","unstructured":"Food and Drug Administration: clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs \u2013 questions and Answers (R3). Guidance for Industry (2017 accessed 26 January 2020)."},{"key":"e_1_3_2_56_2","unstructured":"Food and Drug Administration: E14 clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (2005 accessed 26 January 2020)."},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007724"},{"key":"e_1_3_2_58_2","unstructured":"Zykadia(R) [package insert]. East Hanover NJ: Novartis Pharmaceuticals Corporation 2019."},{"key":"e_1_3_2_59_2","unstructured":"Xalkori(R) [package insert]. New York NY: Pfizer Laboratories Div Pfizer Inc. 2019."},{"key":"e_1_3_2_60_2","unstructured":"Braftovi(R) [package insert]. Boulder CO: Array BioPharma Inc. 2019."},{"key":"e_1_3_2_61_2","unstructured":"Rozlytrek TM [package insert]. South San Francisco: Genentech Inc. 2019."},{"key":"e_1_3_2_62_2","unstructured":"Xospata(R) [package insert]. Northbrook IL: Astellas Pharma US Inc. 2019."},{"key":"e_1_3_2_63_2","unstructured":"Daurismo TM [package insert]. New York NY: Pfizer Laboratories Div Pfizer Inc. 2019."},{"key":"e_1_3_2_64_2","unstructured":"Tibsovo(R) [package insert]. Cambridge MA: Agios Pharmaceuticals Inc. 2019."},{"key":"e_1_3_2_65_2","unstructured":"Tykerb(R) [package insert]. East Hanover NJ: Novartis Pharmaceuticals Corporation 2019."},{"key":"e_1_3_2_66_2","unstructured":"Tasigna(R) [package insert]. East Hanover NJ: Novartis Pharmaceuticals Corporation 2019."},{"key":"e_1_3_2_67_2","unstructured":"Tagrisso(R) [package insert]. Wilmington DE: AstraZeneca Pharmaceuticals LP 2019."},{"key":"e_1_3_2_68_2","unstructured":"Kisqali(R) [package insert]. East Hanover NJ: Novartis Pharmaceuticals Corporation 2019."},{"key":"e_1_3_2_69_2","unstructured":"Zelboraf(R) [package insert]. South San Francisco CA: Genentech Inc. 2018."},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jons.2018.07.003"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2014.954546"},{"key":"e_1_3_2_72_2","unstructured":"FDA Drug Safety Communication: abnormal heart rhythms associated with use of Anzemet (dolasetron mesylate) (accessed 15 April 2020)."},{"key":"e_1_3_2_73_2","unstructured":"Ettinger DS Berger MJ Barvour S et\u00a0al. Antiemesis (2020 accessed 15 April 2020)."},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.780026"},{"key":"e_1_3_2_75_2","unstructured":"FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran) (accessed 15 April 2020)."},{"key":"e_1_3_2_76_2","unstructured":"Sancuso (R) [package insert]. Bedminster NJ: Kyowa Kirin Inc. 2017."},{"key":"e_1_3_2_77_2","unstructured":"Aloxi(R) [packge insert]. Woodcliff Lake NJ: Eisai Inc. 2015."},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0069-5"},{"key":"e_1_3_2_79_2","unstructured":"Baden LR Swaminathan S. Prevention and treatment of cancer-related infections. In: NCCN clinical practice guidelines in oncology. Plymouth Meeting PA: National Comprehensive Cancer Network 2017 p. INF-1 through p. MS-113."},{"key":"e_1_3_2_80_2","unstructured":"Cresemba [package insert]. Northbrook IL: Astellas Pharma US Inc. 2019."}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220958462","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220958462","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220958462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:23:45Z","timestamp":1777688625000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220958462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,21]]},"references-count":79,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1177\/1078155220958462"],"URL":"https:\/\/doi.org\/10.1177\/1078155220958462","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,21]]}}}